These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 11060742

  • 21. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.
    Goodman SL, Hölzemann G, Sulyok GA, Kessler H.
    J Med Chem; 2002 Feb 28; 45(5):1045-51. PubMed ID: 11855984
    [Abstract] [Full Text] [Related]

  • 22. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.
    Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA.
    Proc Natl Acad Sci U S A; 1996 Sep 03; 93(18):9764-9. PubMed ID: 8790405
    [Abstract] [Full Text] [Related]

  • 23. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.
    Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, Stins MF, Seeger RC, Durden DL.
    Cancer Res; 2000 Feb 01; 60(3):712-21. PubMed ID: 10676658
    [Abstract] [Full Text] [Related]

  • 24. Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors.
    Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A, Slee AM.
    Anticancer Res; 1999 Feb 01; 19(2A):959-68. PubMed ID: 10368639
    [Abstract] [Full Text] [Related]

  • 25. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis.
    Rüegg C, Alghisi GC.
    Recent Results Cancer Res; 2010 Feb 01; 180():83-101. PubMed ID: 20033379
    [Abstract] [Full Text] [Related]

  • 26. The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3.
    Ludbrook SB, Barry ST, Delves CJ, Horgan CM.
    Biochem J; 2003 Jan 15; 369(Pt 2):311-8. PubMed ID: 12358597
    [Abstract] [Full Text] [Related]

  • 27. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
    Raboisson P, Manthey CL, Chaikin M, Lattanze J, Crysler C, Leonard K, Pan W, Tomczuk BE, Marugán JJ.
    Eur J Med Chem; 2006 Jul 15; 41(7):847-61. PubMed ID: 16697080
    [Abstract] [Full Text] [Related]

  • 28. Alpha-v integrins as therapeutic targets in oncology.
    Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, Corringham R, Prabhakar U, Davis HM, Beckman RA.
    Cancer Invest; 2007 Oct 15; 25(7):632-46. PubMed ID: 18027153
    [Abstract] [Full Text] [Related]

  • 29. Design, synthesis and biological evaluation of nonpeptide integrin antagonists.
    Nicolaou KC, Trujillo JI, Jandeleit B, Chibale K, Rosenfeld M, Diefenbach B, Cheresh DA, Goodman SL.
    Bioorg Med Chem; 1998 Aug 15; 6(8):1185-208. PubMed ID: 9784861
    [Abstract] [Full Text] [Related]

  • 30. Vitronectin receptors in vascular disorders.
    Mousa SA.
    Curr Opin Investig Drugs; 2002 Aug 15; 3(8):1191-5. PubMed ID: 12211413
    [Abstract] [Full Text] [Related]

  • 31. Targeting integrins for the control of tumour angiogenesis.
    Akalu A, Cretu A, Brooks PC.
    Expert Opin Investig Drugs; 2005 Dec 15; 14(12):1475-86. PubMed ID: 16307488
    [Abstract] [Full Text] [Related]

  • 32. Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.
    Perron-Sierra F, Saint Dizier D, Bertrand M, Genton A, Tucker GC, Casara P.
    Bioorg Med Chem Lett; 2002 Nov 18; 12(22):3291-6. PubMed ID: 12392735
    [Abstract] [Full Text] [Related]

  • 33. Novel integrin antagonists derived from thrombospondins.
    Calzada MJ, Roberts DD.
    Curr Pharm Des; 2005 Nov 18; 11(7):849-66. PubMed ID: 15777239
    [Abstract] [Full Text] [Related]

  • 34. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications.
    Mousa SA.
    Curr Opin Chem Biol; 2002 Aug 18; 6(4):534-41. PubMed ID: 12133730
    [Abstract] [Full Text] [Related]

  • 35. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
    Lele M, Sajid M, Wajih N, Stouffer GA.
    Circulation; 2001 Jul 31; 104(5):582-7. PubMed ID: 11479257
    [Abstract] [Full Text] [Related]

  • 36. The biology of integrins.
    Stupack DG.
    Oncology (Williston Park); 2007 Aug 31; 21(9 Suppl 3):6-12. PubMed ID: 17927025
    [Abstract] [Full Text] [Related]

  • 37. alpha(v)beta(3) Integrin antagonists as inhibitors of bone resorption.
    Hartman GD, Duggan ME.
    Expert Opin Investig Drugs; 2000 Jun 31; 9(6):1281-91. PubMed ID: 11060743
    [Abstract] [Full Text] [Related]

  • 38. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
    Yeh CH, Peng HC, Yang RS, Huang TF.
    Mol Pharmacol; 2001 May 31; 59(5):1333-42. PubMed ID: 11306719
    [Abstract] [Full Text] [Related]

  • 39. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
    Rüegg C, Dormond O, Mariotti A.
    Biochim Biophys Acta; 2004 Mar 04; 1654(1):51-67. PubMed ID: 14984767
    [Abstract] [Full Text] [Related]

  • 40. Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.
    Trabocchi A, Menchi G, Cini N, Bianchini F, Raspanti S, Bottoncetti A, Pupi A, Calorini L, Guarna A.
    J Med Chem; 2010 Oct 14; 53(19):7119-28. PubMed ID: 20809642
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.